LD
ADVM

Lipe & Dalton’s Adverum Biotechnologies ADVM Stock Holding History

Lipe & Dalton’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,500
Closed -$11K – 106
2023
Q4 		$11K Hold
1,500
– – 0.01% 102
2023
Q3 		$22K Hold
1,500
– – 0.01% 96
2023
Q2 		$24K Hold
1,500
– – 0.01% 97
2023
Q1 		$11K Hold
1,500
– – 0.01% 100
2022
Q4 		$9K Hold
1,500
– – 0.01% 99
2022
Q3 		$14K Hold
1,500
– – 0.01% 100
2022
Q2 		$18K Hold
1,500
– – 0.01% 95
2022
Q1 		$20K Hold
1,500
– – 0.01% 101
2021
Q4 		$26K Hold
1,500
– – 0.01% 104
2021
Q3 		$33K Hold
1,500
– – 0.02% 98
2021
Q2 		$52K Buy
+1,500
New +$80.8K 0.03% 96

Other funds holding ADVM

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Lipe & Dalton's ADVM Position: Q1 2024 in Review

Lipe & Dalton sold out of Adverum Biotechnologies (ADVM) in Q1 2024, closing a stake of 1,500 shares — an estimated $11K sold.

Lipe & Dalton first reported a position in ADVM in Q2 2021 and held it in 11 quarters. The position peaked at $52K in Q2 2021. 61 funds tracked by Wall St. Rank hold ADVM as of Q1 2024.

  • Lipe & Dalton reported no remaining Adverum Biotechnologies position as of Q1 2024 after selling out during the quarter.
  • Lipe & Dalton sold 1,500 Adverum Biotechnologies shares in Q1 2024, an estimated $11K.
  • Lipe & Dalton first reported a position in Adverum Biotechnologies in Q2 2021 and held it in 11 quarters.
  • Lipe & Dalton's Adverum Biotechnologies position peaked at $52K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2024.

Based on Lipe & Dalton's 13F filing for Q1 2024, filed 7 May 2024.